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MR‑proADM as prognostic factor 
of outcome in COVID‑19 patients
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Alessandro Giacinta1, Valentina Gerussi1, Daniela Visentini2, Paola De Stefanis3, 
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Mid Regional pro‑ADM (MR‑proADM) is a promising novel biomarker in the evaluation of deteriorating 
patients and an emergent prognosis factor in patients with sepsis, septic shock and organ failure. It 
can be induced by bacteria, fungi or viruses. We hypothesized that the assessment of MR‑proADM, 
with or without other inflammatory cytokines, as part of a clinical assessment of COVID‑19 patients 
at hospital admission, may assist in identifying those likely to develop severe disease. A pragmatic 
retrospective analysis was performed on a complete data set from 111 patients admitted to Udine 
University Hospital, in northern Italy, from 25th March to 15th May 2020, affected by SARS‑CoV‑2 
pneumonia. Clinical scoring systems (SOFA score, WHO disease severity class, SIMEU clinical 
phenotype), cytokines (IL‑6, IL‑1b, IL‑8, TNF‑α), and MR‑proADM were measured. Demographic, 
clinical and outcome data were collected for analysis. At multivariate analysis, high MR‑proADM 
levels were significantly associated with negative outcome (death or orotracheal intubation, IOT), 
with an odds ratio of 4.284 [1.893–11.413], together with increased neutrophil count (OR = 1.029 
[1.011–1.049]) and WHO disease severity class (OR = 7.632 [5.871–19.496]). AUROC analysis showed 
a good discriminative performance of MR‑proADM (AUROC: 0.849 [95% Cl 0.771–0.730]; p < 0.0001). 
The optimal value of MR‑proADM to discriminate combined event of death or IOT is 0.895 nmol/l, with 
a sensitivity of 0.857 [95% Cl 0.728–0.987] and a specificity of 0.687 [95% Cl 0.587–0.787]. This study 
shows an association between MR‑proADM levels and the severity of COVID‑19. The assessment of 
MR‑proADM combined with clinical scoring systems could be of great value in triaging, evaluating 
possible escalation of therapies, and admission avoidance or inclusion into trials. Larger prospective 
and controlled studies are needed to confirm these findings.
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OR  Odds ratio
PaO2  Arterial oxygen tension
PCT  Procalcitonin
ROC  Receiver-operator characteristic
SARS-CoV-2  Severe acute respiratory syndrome coronavirus two
SIMEU  Italian society of emergency and urgency medicine
SOFA  Sequential organ failure assessment
The pathological mechanisms of organ damage in Coronavirus disease 2019 (COVID-19) patients remain poorly 
understood. The leading cause of mortality in patients with COVID-19 is hypoxic respiratory failure from acute 
respiratory distress syndrome (ARDS)1. The multiple organ failure described in COVID-19 suggests a multi-
pathway involvement.
Evidence suggests that pulmonary endothelial cells (ECs) contribute to the initiation and propagation of 
ARDS by altering vascular barrier integrity, promoting a pro-coagulative state, inducing vascular inflammation 
(endotheliitis), tissue edema and mediating inflammatory cell  infiltration2. Severe Acute Respiratory Syndrome 
Coronavirus two (SARS-CoV-2) virus binds Angiotensin Converting Enzyme 2 (ACE2) receptor and induces 
a down-regulation of ACE2 that results in activation of kallikrein–bradykinin pathway, increasing vascular 
 permeability3.
Cytokine storm has been postulated in COVID-19, at least in the last phase during  ARDS4,5 amplifying the 
destructive process by leading to further endothelial cells dysfunction and vasodilation of the pulmonary capil-
lary  bed6,7. The experiences of Sinha et al. and of Kox et al. showed elevated IL-6 levels in severe COVID-19, as 
observed in other critically ill patients; at the same time, IL-6 levels in COVID-19 were lower than in patients 
with bacterial  sepsis4,5.
The alteration of vascular barrier integrity, the pro-coagulative state, endotheliiyis and the cytokine storm 
might contribute to the progression towards ARDS and ultimately to multi-organ failure and  death8.
The role of biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP) is already well established 
in infections; the PCT and CRP dosing are routinely used to confirm the presence of infection and in the follow-
up during medical treatment. Recently, Adrenomedullin (ADM) or, more precisely, its stable protein surrogate 
Mid Regional pro-Adrenomedullin (MR-proADM), gained interest as a major player in deteriorating patients. 
MR-proADM plays a role in vascular permeability, inflammatory mediation, endothelial barrier regulation and 
stabilization of the microcirculation, all of which contribute to the development of organ dysfunction and failure 
in sepsis and septic shock. Therefore, the increase of MR-proADM is seen as an indicator of organ dysfunction 
and, unlike most other biomarkers, it is essential in maintaining endothelial stability. For this reason, it may be 
a relevant biomarker to understand the ECs.
Saeed et al. have studied MR-proADM in patients presenting to the emergency department with a suspected 
infection and they proposed two major clinical uses for it: 1) An early escalation of antibiotic and resuscitation 
treatment in patients with MR-proADM values > 1,5 nmol/L, as such high MR-proADM concentrations identify 
severe illness and a potential for further progression of the disease; 2) A potential reduction of the number of 
hospitalizations and re-admissions for patients with MR-proADM values < 0,9 nmol/L, that is the absence of 
endothelial  damage9. MR-proADM identifies disease severity and treatment response more accurately than 
established biomarkers and scores indeed [ 10].
MR-proADM may also be of interest within COVID-19 induced  endotheliitis11, but only two studies have 
described the potential role of this biomarker in COVID-19 patients so far. The first study evaluated only 20 
patients with COVID-19, measuring adrenomedullin RNA expression and the authors found a correlation 
between RNA expression and severity of the  disease12. In the second study, Montruccio et al.found higher levels 
of MR-proADM in COVID-19 patients admitted to Intensive Care Unit (ICU) and hence they suggested that MR-
proADM can be used as a predictor factor of disease progression and mortality, with a cut-off value > 1,8 nmol/
L13.
At Udine University Hospital, a number of biomarkers including MR-proADM and other cytokines have 
been implemented during the first wave of COVID-19 outbreak.
We hypothesized that the assessment of MR-proADM, with or without other inflammatory cytokines, as part 
of a clinical assessment of COVID-19 patients at hospital admission, may assist in identifying those likely to 
develop severe disease, facilitating triaging and decision-making about possible treatment escalations.
Materials and methods
Patient population. A pragmatic retrospective analysis of 111 COVID-19 patients admitted to Udine Uni-
versity Hospital, in northeast Italy, from 25th March to 15th May 2020, was conducted. All the included cases 
had the diagnosis of SARS-CoV-2 pneumonia and for all of them was possible to make a complete review of the 
data set.
All patients enrolled had positive PCR test for SARS-CoV-2 and features of respiratory infection, evaluated 
with radiologic chest imaging (chest CT, chest XR and/or Point-of-Care Ultrasound) and other clinical signs.
SARS-CoV-2 infection status was evaluated by PCR on nasopharyngeal swabs. The mean interval between 
symptom presentation and swab sample collection was found to be 6 days  [CI95 3–9].
The full spectrum of COVID-19 ranged from mild, self-limiting respiratory tract illness, to severe progres-
sive pneumonia, multi-organ failure, and death. The clinical severity of patients suffering from COVID-19 was 
evaluated using the classification reported on World Health Organization  guidance14 and the Italian Society of 
Emergency and Urgency Medicine (SIMEU) clinical  phenotypes15.
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For all the patients enrolled in this study the following parameters were recorded: age, gender, Charlson 
comorbidity index, length of hospital stays, sequential organ failure assessment score value (SOFA score) at 
admission, clinical severity as already described, and  PaO2/FiO2 at admission. Furthermore, during hospitaliza-
tion, the following markers were measured in all the included patients: white blood cells count, encompassing 
neutrophils, lymphocytes and the ratio CD4/CD8, platelets count, creatinine, bilirubin, CRP, PCT, D-dimer, 
lactate dehydrogenase (LDH), Creatine Kinase (CK), B-type natriuretic peptide, high-sensitive cardiac troponin, 
IL-6, IL-1b, IL-8, TNF-α, and MR-proADM.
A negative outcome was defined by a combination of death and orotracheal intubation (IOT) during 
hospitalization.
All research was performed in accordance with the relevant guidelines and regulations. This study was 
approved by the Friuli Venezia Giulia ethics committee and the informed and written consent was obtained 
from the participants.
Laboratory methods. Real-time reverse transcriptase-PCR assays for the detection of SARS-CoV-2 on 
upper respiratory specimens collected from swabs were conducted at the Virology and Microbiology Laborato-
ries of Udine, according to WHO  guidance16.
MR-proADM plasma concentrations were measured in an automated Kryptor analyzer, using TRACE tech-
nology (Kryptor; BRAHMS, Hennigsdorf, Germany). The lower detection limit was 0.05 nmol/L, while the limit 
Of Quantitation (LOQ) was 0.23 nmol/L. The cut-off for physiological concentration was pointed at 0.56 nmol/L. 
Cytokines were measured by microfluidic ultrasensitive ELISA using the Protein simple plex technology on ELLA 
instrument (R&D systems, Biotechne, USA). The ranges of quantitation are as follows: IL-1β (0.16–1530 pg/ml), 
IL-6 (0.28–2652 pg/ml), IL-8 (0.19–1804 pg/ml), TNF-α (0.30–1160 pg/ml). All the other laboratory biomarkers 
were evaluated using routine certified diagnostic methods.
Statistical analysis. Baseline patient characteristics were summarized using standard descriptive statistics, 
with number and percentages for binary and categorical outcomes and appropriate measures for continuous 
outcomes (e.g. mean ± standard deviation or median and interquartile range, depending on their distribution). 
Accordingly, comparisons between groups were performed with independent sample t-test, Mann–Whitney U 
test or chi-squared test with continuity correction. The relation between outcome and acquired variables was 
investigated with a logistic regression model; the covariates with p < 0.10 at the univariate logistic regression 
were considered for a multivariate stepwise model. Considering the small sample size and the strong correlation 
structure observed in the data, the multivariate regression was computed on a subset of the considered covariate. 
This further process of covariate selection was based on the statistically equivalent signature  algorithm17.
Receiver-operator characteristic (ROC) analysis was used to determine the diagnostic performance of MR-
proADM; jack-knife estimates of sensitivity and specificity were reported at the optimal cutoff point, chosen 
with Youden’s rule.
All analyses were performed with the R statistical  software18. A p value of less than 0.05 was considered to 
be statistically significant.
Study endpoint. Severe disease or negative outcome assessed by the composite end point: the use intuba-
tion mechanical ventilation and/or death.
Results
During the study period (25th March–15th May 2020), 111 patients with COVID-19 were enrolled. Patient char-
acteristics and demographic are summarized in Table 1. The comparison between favorable outcome (83 patients) 
and negative outcome (28 patients) found that factors associated with the second group were (see Table 1): 
gender, higher WHO disease severity class, SIMEU disease severity phenotype, higher SOFA score, lower  PaO2/
FiO2 ratio, lower lymphocytes count, higher level of MR-proADM, IL-6, IL-1b, IL-8, TNFα, white blood cells, 
neutrophils, LDH, CK and C reactive protein. The length of stay was higher in the group with negative outcome.
Factors influencing negative outcome considered as combined events of death or IOT were studied with 
univariate and multivariate analysis and these are summarized in Table 2.
The univariate analysis confirmed that factors associated with negative outcome were (see Table 2): to be male 
(OR 3.25 [1.2565–9.5691]; p = 0.0209), have an higher WHO disease severity class (OR 8.55 [4.1473–21.841]; 
p < 0.0001) and SIMEU disease severity phenotype (OR 4.9577 [3.0004–9.3041]; p < 0.0001), higher SOFA score 
(OR 4.1475 [2.4822–7.9195]; p < 0.0001), lower  PaO2/FiO2 ratio at admission (OR 0.9816 [0.9731–0.9883]; 
p < 0.0001), longer the length of hospital stay (OR 1.1121 [1.0697–1.168]; p < 0.0001), higher level of MR-proADM 
(OR 4.329 [1.9178–12.4701]; p = 0.0024), IL-6 (OR 1.0081 [1.0038–1.0146]; p = 0.0025), TNFalfa (OR 1.1302 
[1.0637–1.2223]; p = 0.0005), C-reactive protein (OR 1.0107 [1.0053–1.0169]; p = 0.0003), white blood cells 
count (OR 1.0187 [1.0081–1.0316]; p = 0.0015), neutrophils count (OR 1.0243 [1.0119–1.0394]; p = 0.0004), 
LDH (OR 1.4282 [1.2105–1.7343]; p = 0.0001), CK (OR 1.3014 [1.0344–1.6797]; p = 0.0296), bilirubin (OR 2.4935 
[0.8597–7.5184]; p = 0.0902), lower levels of lymphocytes (OR 0.9967 [0.9947–0.9983]; p = 0.0002).
The multivariate analysis was able to found three factors associated with negative outcome (see Table 2): higher 
WHO disease severity class (OR = 7.632 [5.871–19.496]; p < 0.0001), MR-proADM (OR = 4.284 [1.893–11.413]; 
p = 0.0006) and neutrophils count (OR = 1.029 [1.011–1.049]; p = 0.0018).
AUROC analysis showed a good discriminative performance of MR-proADM with respect to the combined 
event of death or IOT (AUROC: 0.849 [95% Cl 0.771–0.730]; p < 0.0001, see Fig. 1). The optimal value of MR-
proADM, to discriminate combined event of death or IOT from the group of patients which had a favorable 
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outcome (not dead and not IOT) is 0.895 nmol/l; a sensitivity of 0.857 [95% Cl 0.728–0.987] and a specificity of 
0.687 [95% Cl 0.587–0.787] correspond to this cut-off value of 0.895 nmol/l.
Discussion
We aimed to understand the pathophysiologic behind endothelial damage that might drive a more severe clini-
cal deterioration by evaluating MR-ProADM and other cytokine levels at the point of diagnosis. These protein 
molecules may be used as a guide to differentiate disease severity and to manage the infection. Our findings 
suggest that among all biomarkers and cytokines we looked at, MR-proADM was significantly higher in patients 
hospitalized with COVID-19 and with negative outcome.
MR-proADM could be incorporated as a biomarker in assessing COVID-19 pneumonia severity. MR-
proADM identifies disease severity and treatment response more accurately than established biomarkers (e.g. 
PCT and CRP) and clinical scores in septic  patients10. Clinical scores such as the SOFA score were developed to 
assess the severity of critical patients; specifically, the SOFA score is part of the new definition of sepsis  too19. This 
score is not able to capture individual organ system dysfunction and it is not used in daily routine for COVID-19. 
A quantitative biomarker, if effective, might be more useful than scores in predicting severity of patients. The use 
of a relatively novel biological markers like MR-proADM, which is significantly increased during the initial stages 
of sepsis development, may therefore help in determining or predicting disease severity, guide early diagnostic 
interventions and facilitate more intensive treatment in severe cases before the establishment of further organ 
dysfunction, regardless of the causative agent (bacteria, fungi or viruses)20–22.
Moreover, oxygen requirement/saturation as parameters have been used as triaging tool for COVID-19 
patients during hospital admission. However, when supplemented oxygen has been instituted before an intensiv-
ists’ evaluation, measuring the  PaO2/FiO2 ratio can become very challenging (actually it is known that, if patients 
are not intubated, is almost impossible to know the exact fractional inspired oxygen concentration  (FiO2)). For 
instance, with a nasal cannula set at 2 L/minute,  FiO2 may range anywhere between 24 and 35%. Furthermore, 
saturation as a measure of estimated oximetry might have difference by as much 4%, therefore interpretation of 
 SpO2 above 90% is very difficult due to the sigmoid shape of oxygen dissociation curve. For example, a satura-
tion value of 95% results in a range of arterial oxygen tension  (PaO2) anywhere between 60 and 200 mmHg. In 
Table 1.  Overall study population and comparison between the group with combined event of Death or IOT 
and the group without combined event.
Overall
(n = 111) Not death and not IOT (n = 83)
Death or IOT
(n = 28) p
Males 66 (59.5%) 44 (53.0%) 22 (78.6%) 0.0308
Age (years) 62.29 ± 13.63 61.73 ± 14.28 63.93 ± 11.6 0.4191
WHO disease severity 2.24 ± 1.03 1.86 ± 0.72 3.39 ± 0.96  < 0.0001
SIMEU disease severity 2 [2–3] 2 [2–3] 5 [4–5]  < 0.0001
PaO2/FiO2 ratio 292.5 ± 109.4 330.9 ± 85.6 183.2 ± 96.2  < 0.0001
SOFA score 2 [1–3] 2 [1–2] 3 [3–4]  < 0.0001
Charlson Comorbidity Index 2 [1–4] 2 [1–4] 2.5 [1.75–4] 0.4477
Length of hospital stay (days) 9 [6–22] 7 [4.5–10] 30 [23–47]  < 0.0001
MR-proADM (nMol/L) 0.82 [0.64–1.08] 0.73 [0.56–0.94] 1.38 [0.94–1.73]  < 0.0001
IL-6 (pg/mL) 30.0 [7.7–82.3] 21.9 [4.2–51.0] 175.7 [48.0–1070.0]  < 0.0001
IL-1b (pg/ml) 0.33 [0.18–0.48] 0.28 [0.15–0.42] 0.48 [0.26–0.88] 0.0069
IL-8 (pg/mL) 32.0 [21.0–43.1] 27.7 [18.3–38.4] 37.5 [30.0–62.6] 0.0018
TNFα (pg/mL) 17.0 [13.3–21.8] 16.0 [12.8–19.1] 23.7 [17.6–31.4] 0.0001
C reactive protein (mg/dl) 71.0 [16.9–117.0] 48.0 [10.3–99.5] 108.5 [72.3–200.8] 0.0002
Procalcitonine (mg/dL) 0.07 [0.02–0.29] 0.04 [0.02–0.14] 0.31 [0.18–0.47]  < 0.0001
White blood cell (/mmc) 6020 [4745–7925] 5760 [4330–7465] 7030 [5892–12725] 0.001
Neutrophils (/mmc) 4420 [3130–6680] 3900 [2720–5945] 6175 [4898–11510]  < 0.0001
Lymphocytes (/mmc) 914 ± 435 1007 ± 442 639 ± 268  < 0.0001
CD4/CD8 2.1 [1.4–2.9] 2.0 [1.3–2.9] 2.2 [1.8–4.2] 0.1016
D–dimer (FEUng/ml) 751 [403–1200] 690 [343–1045] 1157 [759.5–1959] 0.0008
LDH (U/L) 517 [375–735] 452 [350–646] 758 [637–951]  < 0.0001
CK (U/L) 92 [55–178] 78 [53–127] 185 [106–333] 0.0002
B-type natriuretic peptide (pg/ml) 28 [12–66] 25 [11–63] 34 [20–92] 0.2634
High-sensitive cardiac troponin (ng/L) 0.02 [0.00–0.02] 0.02 [0.00–0.02] 0.02 [0.00–0.02] 0.3407
Bilirubin (mg/dl) 0.55 [0.40–0.78] 0.51 [0.38–0.78] 0.60 [0.50–0.78] 0.1638
Platelets (/mmc) 224,189 ± 98,333 220,398 ± 85,808 235,429 ± 129,834 0.571
Creatinine (mg/dl) 1.00 ± 0.48 0.98 ± 0.51 1.08 ± 0.37 0.2636
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Table 2.  Factors influencing death or IOT (univariate & multivariate analysis). The variables selected for 
multivariate analysis were: gender, WHO disease severity, MR-proADM, PaO2/FiO2 ratio, IL-6, CD4/CD8, 
Neutrophils count.
Variables
Univariate analysis Multivariate analysis
OR [95% CI] p OR [95% CI]
Males 3.25 [1.2565–9.5691] 0.0209 –
Age (years) 1.0122 [0.9806–1.0465] 0.4607 –
WHO disease severity 8.55 [4.1473–21.841]  < 0.0001 7.632 [5.871–19.496]
SIMEU disease severity 4.9577 [3.0004–9.3041]  < 0.0001 –
PaO2/FiO2 ratio 0.9816 [0.9731–0.9883]  < 0.0001 –
SOFA score 4.1475 [2.4822–7.9195]  < 0.0001 –
Charlson Comorbidity Index 1.0953 [0.9548–1.2742] 0.1949 –
Length of hospital stay (days) 1.1121 [1.0697–1.168]  < 0.0001 –
MR-proADM (nMol/L) 4.329 [1.9178–12.4701] 0.0024 4.284 [1.893–11.413]
IL-6 (pg/mL) 1.0081 [1.0038–1.0146] 0.0025 –
IL-1b (pg/ml) 0.9702 [0.5885–1.2803] 0.8516 –
IL-8 (pg/mL) 1.0119 [0.9995–1.0289] 0.0979 –
TNFα (pg/mL) 1.1302 [1.0637–1.2223] 0.0005 –
C reactive protein (mg/dl) 1.0107 [1.0053–1.0169] 0.0003 –
Procalcitonine (mg/dL) 1.0236 [0.7832–1.2445] 0.7954 –
White blood cell (/mmc) 1.0187 [1.0081–1.0316] 0.0015 –
Neutrophils (/mmc) 1.0243 [1.0119–1.0394] 0.0004 1.029 [1.011–1.049]
Lymphocytes (/mmc) 0.9967 [0.9947–0.9983] 0.0002 –
CD4/CD8 1.3727 [1.0469–1.8571] 0.028 –
D –dimer (FEUng/ml) 1.0112 [0.9981–1.0283] 0.1136 –
LDH (U/L) 1.4282 [1.2105–1.7343] 0.0001 –
CK (U/L) 1.3014 [1.0344–1.6797] 0.0296 –
B-type natriuretic peptide (pg/ml) 1.3294 [1.0285–1.9537] 0.0838 –
High-sensitive cardiac troponin (ng/ml) 1.0306 [1.005–1.0675] 0.0431 –
Bilirubin (mg/dl) 2.4935 [0.8597–7.5184] 0.0902 –
Platelets (/mmc) 1.0015 [0.9971–1.0057] 0.4843 –
Creatinine (mg/dl) 1.477 [0.6115–3.9612] 0.359 –
Figure 1.  AUROC analysis: MR-proADM on combined event of death or orotracheal intubation (IOT). 
AUROC: 0.849 [0.771–0.730], p < 0.0001. Optimal cut-off value of MR-proADM: 0.895; a sensitivity of 0.857 
[0.728–0.987] and a specificity of 0.687 [0.587–0.787] correspond to this cutoff value.
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this scenario, MR-proADM could add a useful piece of information for the correct triage of COVID-19 patients 
and also may become a useful tool in decision-making about enrolling patients into therapeutic clinical  trials23.
Additionally, in accordance with previous studies, MR-ProADM assessment could accurately identify disease 
progression in patients with infection admitted to ED, safely increase out-patients management without increas-
ing the number of re-admissions and/or  mortality9, and identify patients requiring rapid admission to  ICU24. 
In the same papers, the number of viral infections was very low, around 3%, but, considering the findings of 
our study, the hypothesis that MR-proADM might be a stable protein surrogate of severity in COVID-19 could 
be postulate as well. A level of MR-proADM < 0.89 nmol/l could be used together with clinical scoring in the 
ED rooms in COVID-19 patients as a safe admission avoidance tool with safety nets. However, further studies 
should be conducted to confirm this hypothesis.
This is the first study that have evaluated the serum level of MR-proADM in patients admitted to ED for 
SARS-COV-2 pneumonia and that correlates MR-proADM concentration to disease severity of COVID-19.
In fact, Haupf et al. have found an increase of adrenomedullin RNA expression in patients with more severe 
COVID-19 with respect to milder  cases12. Further, ADM expression was not significantly different between 
patients with less severe COVID-19 and patients with other respiratory infections, postulating that endothelii-
tis might be one of the mechanisms involved in severe cases of COVID-19. In the same paper the ROC curve 
for ADM RNA was similar to the value found in our experience with measurement of MR-proADM  protein12.
Montruccio et al. recently demonstrated that a higher mortality was found in patients with MR-proADM 
values higher than 1,8 nmol/L. In the logistic regression model, the odds ratio for mortality of MR-proADM 
was 10,2 and this biomarker had the best predictive ability with respect to age, gender, PCT, PCR, diabetes and 
cardiovascular  diseases13.
In our cohort MR-proADM level was higher in patients with negative outcome, defined as the combination of 
death and IOT during hospitalization (1.38 [0.94–1.73] vs. 0.73 [0.56–0.94]). The multivariate analysis that evalu-
ated factors influencing death or IOT shows that odds ratio of MR-proADM was 4.284 [1.893–11.413], together 
with neutrophil count (OR = 1.029 [1.011–1.049]) and WHO disease severity class (OR = 7.632 [5.871–19.496]).
In the work of Liu et al., neutrophils were significantly higher in severe COVID-19 patients than in mild 
COVID-19 patients at the time of hospital admission. Their study showed that patients with severe COVID-19 
had more serious lymphopenia and increased neutrophil count along with higher levels of circulating pro-
inflammatory cytokines compared to patients with mild COVID-1925. The magnitude of increase in neutrophil 
count may suggest the intensity of inflammatory response in COVID-19 patients.
Many authors have postulated the cytokines storm as the mechanism involved in severe COVID-19 pneu-
monia and many therapeutic approaches have been targeted cytokines in order to reduce the inflammatory 
burden. Recently, some authors have also described that COVID-19 patients with interstitial pneumonia, but 
with no ARDS, have cytokine levels far lower than COVID-19 patients with ARDS. These differences were 
found with different methods of cytokines measurements and also using the same  methods4,5. In our study, the 
MR-proADM value seems more accurate to identify patients with severe COVID-19 pneumonia with respect 
to cytokines, implying that endotheliitis might be more important than the cytokine storm at least in the early 
phase of the disease.
In this study, AUROC analysis showed a good discriminative performance of MR-proADM with respect to 
the combined event of death or IOT (AUROC: 0.849 [95% Cl 0.771–0.730], p < 0.0001). The optimal value of 
MR-proADM to discriminate negative outcome is 0.895 nmol/L with a sensitivity of 0.857 [95% Cl 0.728–0.987] 
and a specificity of 0.687 [95% Cl 0.587–0.787].
Limitations of this study are the retrospective nature of the data collection, the small number of patients 
included compared to the large number of COVID-19 patients that could have been evaluated, and the use of a 
single value of MR-proADM level instead of its kinetics during the whole hospitalization period.
Conclusion
This study shows an association between MR-proADM levels and the severity of COVID-19. The assessment 
of MR-proADM could be of great value in triaging, evaluating possible escalation of therapies and admission 
avoidance or inclusion into trials.
Larger prospective and controlled studies are needed to confirm these findings, to understand if the level of 
MR-proADM might relate to critical care or not, and to investigate the diagnostic potential of MR-proADM as 
a marker of progression to severe COVID-19.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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